Non-squamous Cell Non-Small Cell Lung Cancer Clinical Trial
Official title:
Study of Anlotinib Combined With Pemetrexed as the Second-line Treatment in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer (ALTER-L025)
In recent years, with the progress in the treatment field, NSCLC has become the most
successful cancer species in precision medicine. Patients with positive driving genes such as
EGFR, ALK, ROS1, BRAF and so on have clearly targeted drugs, which bring survival benefits to
patients.However, about 50% of patients still lack a clear driving gene target, which has
become the focus of current research.In the field of wild-type NSCLC with negative driver
genes, the classic first-line treatment regimen is the two-drug regimen containing
platinum.he phase II clinical study of pemetrexed in the second-line treatment of advanced
non-small cell lung cancer patients with pemetrexed versus carboplatin pemetrexed showed that
the median PFS time in the pemetrexed group was 3.5 months.
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and
development.In the phase Ⅲ study, patients who failed at least two kinds of systemic
chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib or
placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group
PFS and OS were 1.4 months and 6.3 months.
The efficacy and safety of anrotinib combined with pemetrexed in the second-line treatment of
advanced non-squamous and non-small cell patients deserve further exploration.
This is a multicentre single arm clinical trial conducted in China,the purpose of this study is to evaluate and observe Anlotinib (12mg QD PO d1-14, 21 days per cycle) Combined With Pemetrexed(500mg/m2,IV,d1,21 days per cycle) as the second-line Treatment in Patients With Advanced nonsquamous Non-Small-Cell Lung Cancer.As the report,The median PFS of advanced NSCLC treated by Pemetrexed as second-line was 3-3.5 months.We expect the median PFS of Anlotinib combined with Pemetrexed as the second-line Treatment in Patients With Advanced nonsquamous NSCLC was 6 months.Using PASS15, we calculated the sample size of this study was 46(α=0.025、β=0.1), according to 10% censoring,the expected sample size is 51. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01673867 -
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
|
Phase 3 | |
| Recruiting |
NCT03790228 -
Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC
|
Phase 1 | |
| Not yet recruiting |
NCT03792074 -
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
|
Phase 3 |